Taking peopleNo phase
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
Key facts
- Who runs it
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- Where
- France9 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 Nov 2024
- Planned end
- Dec 2025
- Type of study
- Observational
- Record updated
- 15 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients aged 18 and older with moderate to severe orbitopathy
- Patients followed in endocrinology with the goal of achieving euthyroidism
- Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS)
- Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy
- Patients with a CAS ≥ 3 or CAS <3 with moderate to severe orbitopathy (according to EUGOGO)
- Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment
- Patients who are not opposed to the reuse of their health data
Who cannot take part
- Patients who have undergone bone or fat decompression surgery
- Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy
- Patients with severe corneal involvement (Grade B or C; NO SPECS classification)
- Patients with optic neuropathy (Grade B and C; NO SPECS classification)
- Patients who have opposed the reuse of their health data
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow
- Record updated
- 15 August 2025